Black seed drug trial for liver cancer pulled before start
NCT ID NCT06217094
First seen Oct 31, 2025 · Last updated May 19, 2026 · Updated 29 times
Summary
This early-stage study aimed to test a drug made from black seed (NP-101) alongside standard radiation therapy for people with liver cancer that cannot be removed by surgery. The goal was to find the safest dose and see if it could help control the cancer. However, the study was withdrawn before any participants were enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Florida
Gainesville, Florida, 32608, United States
Conditions
Explore the condition pages connected to this study.